BR0311247A - Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2 - Google Patents

Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2

Info

Publication number
BR0311247A
BR0311247A BR0311247-0A BR0311247A BR0311247A BR 0311247 A BR0311247 A BR 0311247A BR 0311247 A BR0311247 A BR 0311247A BR 0311247 A BR0311247 A BR 0311247A
Authority
BR
Brazil
Prior art keywords
prostaglandin
group
receptor antagonist
hydrogen atom
antagonist peptide
Prior art date
Application number
BR0311247-0A
Other languages
English (en)
Inventor
Krishna G Peri
Serge Moffett
Daniel Abran
Annie Bergeron
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of BR0311247A publication Critical patent/BR0311247A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"PEPTìDEOS ANTAGONISTAS DO RECEPTOR SUBTIPO EP4 DA PROSTAGLANDINA E2". São descritos peptídeos antagonistas do receptor subtipo EP4 da prostaglandina E2 e sua utilização no tratamento ou prevenção de condições médicas associadas a nefropatia oligoúrica, reabsorção óssea, proliferação da célula da cripta intestinal ou da persistência do canal arterial e semelhantes. Os petídeos antagonistas da presente invenção possuem como fórmula (I) geral: Em que X é selecionado do grupo que consiste de um átomo de hidrogênio, uma seq³ência de 1 a 3 aminoácidos e grupos de proteção, tais como grupo carbamato e um grupo acila; e em que Y é selecionado do grupo que consiste de um átomo de hidrogênio, 1 a 5 resíduos de L-lisina, fosfato, sulfato e 1 a 5 resíduos de etileno glicol.
BR0311247-0A 2002-05-23 2003-05-23 Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2 BR0311247A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38233602P 2002-05-23 2002-05-23
PCT/CA2003/000771 WO2003099857A1 (en) 2002-05-23 2003-05-23 Antagonistic peptides of prostaglandin e2 receptor subtype ep4

Publications (1)

Publication Number Publication Date
BR0311247A true BR0311247A (pt) 2005-03-15

Family

ID=29584392

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311247-0A BR0311247A (pt) 2002-05-23 2003-05-23 Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2

Country Status (8)

Country Link
US (1) US20040023853A1 (pt)
EP (1) EP1506220A1 (pt)
JP (1) JP2006506327A (pt)
CN (1) CN1662551A (pt)
AU (1) AU2003233297A1 (pt)
BR (1) BR0311247A (pt)
CA (1) CA2485485A1 (pt)
WO (1) WO2003099857A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536208A (ja) * 2004-05-03 2007-12-13 アステラス製薬株式会社 腎疾患を処置するためのプロスタグランジンｅ２レセプターアンタゴニストおよびレニン−アンジオテンシン系インヒビターの組み合わせ
US20060115785A1 (en) * 2004-11-30 2006-06-01 Chunhua Li Systems and methods for intra-oral drug delivery
EP2029044A4 (en) * 2006-06-06 2009-11-04 Reika Ortho Technologies Inc ORTHODONTIC TRANSMISSION DEVICES
CN101041687B (zh) * 2007-02-28 2010-09-29 长春博泰医药生物技术有限责任公司 Pge2特异结合的噬菌体环七肽及筛选方法和合成肽的用途
WO2010087425A1 (ja) 2009-01-30 2010-08-05 国立大学法人京都大学 前立腺癌の進行抑制剤および進行抑制方法
KR101857310B1 (ko) 2010-09-29 2018-05-11 가부시키가이샤 에누비 켄코우겡큐쇼 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체
HUE039015T2 (hu) 2013-06-12 2018-12-28 Kaken Pharma Co Ltd 4-Alkinil-imidazol-származék és ezt hatóanyagként tartalmazó gyógyszerkészítmény
TW201623277A (zh) * 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
US10279044B2 (en) 2015-05-29 2019-05-07 Purdue Research Foundation Bone fracture repair by targeting of agents that promote bone healing
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018210992A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
KR102626982B1 (ko) 2017-05-18 2024-01-18 이도르시아 파마슈티컬스 리미티드 Pge2 수용체 조절제로서의 피리미딘 유도체
AU2018269666B2 (en) 2017-05-18 2022-02-03 Idorsia Pharmaceuticals Ltd Phenyl derivatives as PGE2 receptor modulators
PT3625224T (pt) 2017-05-18 2021-10-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-substituídos
WO2022102731A1 (ja) 2020-11-13 2022-05-19 小野薬品工業株式会社 Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605814A (en) * 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
TWI247606B (en) * 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
MXPA02005626A (es) * 1999-12-06 2004-09-10 Pital Sainte Justine H Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.

Also Published As

Publication number Publication date
EP1506220A1 (en) 2005-02-16
JP2006506327A (ja) 2006-02-23
WO2003099857B1 (en) 2004-02-19
CN1662551A (zh) 2005-08-31
WO2003099857A1 (en) 2003-12-04
AU2003233297A2 (en) 2003-12-12
AU2003233297A1 (en) 2003-12-12
US20040023853A1 (en) 2004-02-05
CA2485485A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
BR0311247A (pt) Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2
DE60119968T2 (de) Hepatitis c tripeptid inhibitoren
CN1136915C (zh) 九肽和十肽在治疗艾滋病药物的制备中的应用
SK2052001A3 (en) Peptide analogues, process for their preparation, pharmaceutical composition containing same, their use and intermediates
CA2660183C (en) Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer
DE60324552D1 (en) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
Takagi et al. Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity
BRPI0516825A (pt) inibição da protease ns3-ns4a do vìrus da hepatite c (vhc)
ATE481106T1 (de) Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
GB2431404A (en) Peptide
BR0013248A (pt) Inibidores da adesão celular
AU2003299519A8 (en) Hepatitis c virus inhibitors
DE60329201D1 (de) Substituierte wt1-peptide
BR9808017A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratar o câncer em um mamìfero e para a fabricação de um medicamento para o tratamento do câncer
CY1107990T1 (el) Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων
AU638468B2 (en) Hemoregulatory peptides
CN88103009A (zh) 环状抗凝血肽的制备方法
MY147920A (en) Antibacterial and antiviral peptides from actinomadura namibiensis
CA1327869C (en) Ribonucleotide reductase inhibitors
EA200400603A1 (ru) Новые пептиды - аналоги гормона высвобождения гормона роста человека
RU2008125167A (ru) Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента дезацил-грелин и его производные
EP1878741A3 (en) Antagonistic peptides of prostaglandin E2 receptor subtype EP4
Stefanowicz et al. Threonine at position 6 is not essential for the immunosuppressive activity of HLA-DQ (β164–172)-hexapeptide
JP2005126360A (ja) 新規なポリペプチドで構成されたコラゲナーゼ阻害剤
Anuradha et al. Stimulation of nonspecific resistance by thymopentin and its analogs against Leishmania donovani infection in hamsters

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.